## Whady Hueb

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3911920/publications.pdf

Version: 2024-02-01

117453 39575 9,279 137 34 94 citations g-index h-index papers 174 174 174 7099 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Death and Myocardial Infarction Following Initial Revascularization Versus Optimal Medical Therapy in Chronic Coronary Syndromes With Myocardial Ischemia: A Systematic Review and Metaâ€Analysis of Contemporary Randomized Controlled Trials. Journal of the American Heart Association, 2021, 10, e019114.	1.6	15
2	Surgical and percutaneous revascularization outcomes based on SYNTAX I, II, and residual scores: a long-term follow-up study. Journal of Cardiothoracic Surgery, 2021, 16, 248.	0.4	1
3	Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial. Nephrology Dialysis Transplantation, 2020, 35, 1369-1376.	0.4	13
4	Lipid transfer to HDL, CETP and HDL composition in coronary artery disease patients with or without type 2 diabetes mellitus. European Journal of Preventive Cardiology, 2020, 27, 2223-2225.	0.8	О
5	Stress Testing and Risk Prediction in People With Known Symptomatic Multivessel Coronary Artery Disease—Reply. JAMA Internal Medicine, 2020, 180, 166.	2.6	O
6	EFFECT OF MYOCARDIAL ISCHEMIA IN DIABETIC AND NON-DIABETIC PATIENTS: LONG-TERM FOLLOW-UP OF MASS REGISTRY. Journal of the American College of Cardiology, 2020, 75, 109.	1.2	0
7	Long-term prognostic value of late gadolinium enhancement and periprocedural myocardial infarction after uncomplicated revascularization: MASS-V follow-up. European Heart Journal Cardiovascular Imaging, 2020, , .	0.5	2
8	Initial Invasive or Conservative Strategy for Stable Coronary Disease. New England Journal of Medicine, 2020, 382, 1395-1407.	13.9	1,508
9	Significant association of SYNTAX score on release of cardiac biomarkers in uncomplicated post-revascularization procedures among patients with stable multivessel disease. Medicine (United) Tj $ETQq1\ 1$	. 0. <b>084</b> 314	4 rgBT /Over <mark>lo</mark>
10	Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease. JAMA Network Open, 2020, 3, e1919666.	2.8	14
11	Hypotheses, rationale, design, and methods for prognostic evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy who undergo medical or surgical treatment: MASS-VI (HF). Trials, 2020, 21, 337.	0.7	2
12	Abstract 13660: Initial Revascularization in Chronic Coronary Syndromes With Myocardial Ischemia. Circulation, 2020, 142, .	1.6	0
13	APPLICATION OF SYNTAX SCORE I, II AND RESIDUAL SYNTAX AS PREDICTORS OF LONG-TERM CLINICAL OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING. Journal of the American College of Cardiology, 2019, 73, 174.	1.2	O
14	Association Between Stress Testing–Induced Myocardial Ischemia and Clinical Events in Patients With Multivessel Coronary Artery Disease. JAMA Internal Medicine, 2019, 179, 1345.	2.6	24
15	VERY LONG-TERM FOLLOW-UP OF DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING ANGIOPLASTY WITH CONVENTIONAL AND DRUG-ELUTING STENTS. Journal of the American College of Cardiology, 2019, 73, 137.	1.2	O
16	Clinical significance of chronic myocardial ischemia in coronary artery disease patients. Journal of Thoracic Disease, 2019, 11, 1005-1015.	0.6	34
17	Effect of ischemic preconditioning on cardiovascular outcomes in patients with symptomatic coronary artery disease. Coronary Artery Disease, 2019, 30, 536-541.	0.3	O
18	Long-Term Survival Following MultivesselÂRevascularization in PatientsÂWith Diabetes. Journal of the American College of Cardiology, 2019, 73, 629-638.	1.2	190

#	Article	IF	CITATIONS
19	Ten-Year Follow-Up of Off-Pump and On-Pump Multivessel Coronary Artery Bypass Grafting: MASS III. Angiology, 2019, 70, 337-344.	0.8	11
20	Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet, The, 2018, 391, 939-948.	6.3	506
21	Chronic Kidney Disease and Coronary Artery Disease. , 2018, , .		2
22	Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. Cost Effectiveness and Resource Allocation, 2018, 16, 55.	0.6	10
23	SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization in the FREEDOM Trial. Journal of the American College of Cardiology, 2018, 72, 2826-2837.	1.2	42
24	Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 2018, 72, 386-398.	1.2	89
25	Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: Results from the MASS III trial. International Journal of Cardiology, 2018, 273, 63-68.	0.8	5
26	Better Technology, More Spending, Worse Outcomes. Arquivos Brasileiros De Cardiologia, 2018, 110, 331-332.	0.3	0
27	Large Bilateral Coronary Artery Fistula: 10-year follow-up in Clinical Treatment. Arquivos Brasileiros De Cardiologia, 2018, 112, 211-213.	0.3	О
28	Single Photon Computed Tomography-Myocardial Perfusion Scintigraphy. Diagnostic Tool Anticipating the Disease. Arquivos Brasileiros De Cardiologia, 2018, 112, 129.	0.3	1
29	Behavior of Ultrasensitive C-Reactive Protein in Myocardial Revascularization with and without Cardiopulmonary Bypass. Brazilian Journal of Cardiovascular Surgery, 2018, 33, 535-541.	0.2	0
30	SYNTAX Score and Long-TermÂOutcomes. Journal of the American College of Cardiology, 2017, 69, 395-403.	1.2	54
31	Biomarker release after percutaneous coronary intervention in patients without established myocardial infarction as assessed by cardiac magnetic resonance with late gadolinium enhancement. Catheterization and Cardiovascular Interventions, 2017, 90, 87-93.	0.7	5
32	COST-EFFECTIVENESS ANALYSIS AND QUALITY OF LIFE OF ON-PUMP AND OFF-PUMP STABLE MULTIVESSEL CORONARY ARTERY BYPASS GRAFTING: MASS III TRIAL 5-YEAR FOLLOW-UP. Journal of the American College of Cardiology, 2017, 69, 100.	1.2	0
33	Differences in lipid transfers to HDL between patients with coronary arterial disease with or without type 2 diabetes mellitus. Atherosclerosis, 2017, 263, e217.	0.4	0
34	Significant elevation of biomarkers of myocardial necrosis after coronary artery bypass grafting without myocardial infarction established assessed by cardiac magnetic resonance. Medicine (United) Tj ETQq0 (	) OorgeBT /(	Overlock 10 Tf
35	Utility and quality-adjusted life-years in coronary artery disease. Medicine (United States), 2017, 96, e9113.	0.4	11
36	Abnormal elevation of myocardial necrosis biomarkers after coronary artery bypass grafting without established myocardial infarction assessed by cardiac magnetic resonance. Journal of Cardiothoracic Surgery, 2017, 12, 122.	0.4	4

#	Article	IF	CITATIONS
37	Myocardial injury in diabetic patients with multivessel coronary artery disease after revascularization interventions. Diabetology and Metabolic Syndrome, 2017, 9, 92.	1.2	5
38	The Influence of Diabetes Mellitus in Myocardial Ischemic Preconditioning. Journal of Diabetes Research, 2016, 2016, 1-6.	1.0	2
39	Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. Kidney International, 2016, 90, 411-421.	2.6	38
40	Impact of Chronic Kidney Disease on Long-Term Outcomes in Type 2 Diabetic Patients With Coronary Artery Disease on Surgical, Angioplasty, or Medical Treatment. Annals of Thoracic Surgery, 2016, 101, 1735-1744.	0.7	16
41	Accuracy of Myocardial Biomarkers in the Diagnosis of Myocardial Infarction After Revascularization as Assessed by Cardiac Resonance: The Medicine, Angioplasty, Surgery Study V (MASS-V) Trial. Annals of Thoracic Surgery, 2016, 101, 2202-2208.	0.7	20
42	Interventional therapies in ischemic ventricular dysfunction: facts and versions!. Annals of Translational Medicine, 2016, 4, S27-S27.	0.7	2
43	The challenge of treating elderly coronary artery disease patients. Journal of Thoracic Disease, 2016, 8, 1434-1436.	0.6	3
44	Role of Trimetazidine in Ischemic Preconditioning in Patients With Symptomatic Coronary Artery Disease. Medicine (United States), 2015, 94, e1161.	0.4	5
45	Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2015, 14, 107.	2.7	26
46	Type 2 diabetes mellitus and myocardial ischemic preconditioning in symptomatic coronary artery disease patients. Cardiovascular Diabetology, 2015, 14, 66.	2.7	17
47	Effects of Glycemic Control upon Serum Lipids and Lipid Transfers to HDL in Patients with Type 2 Diabetes Mellitus: Novel Findings in Unesterified Cholesterol Status. Experimental and Clinical Endocrinology and Diabetes, 2015, 123, 232-239.	0.6	12
48	Recurrent Angina Caused by Coronary Subclavian Steal Syndrome Confirmed by Positron Emission Tomography. Annals of Thoracic Surgery, 2015, 99, e111-e114.	0.7	2
49	Troponin in diabetic patients with and without chronic coronary artery disease. BMC Cardiovascular Disorders, 2015, 15, 72.	0.7	34
50	Comparison between off-pump and on-pump coronary artery bypass grafting in patients with severe lesions at the circumflex artery territory: 5-year follow-up of the MASS III trial. European Journal of Cardio-thoracic Surgery, 2015, 47, 455-458.	0.6	7
51	Conservative strategy for treatment of stable coronary artery disease. World Journal of Clinical Cases, 2015, 3, 163.	0.3	4
52	On-pump versus off-pump coronary artery bypass surgery in patients older than 60Âyears: five-year follow-up of MASS III trial. Journal of Cardiothoracic Surgery, 2014, 9, 127.	0.4	5
53	A case of mid-apical obstructive hypertrophic cardiomyopathy treated with a transapical myectomy approach: a case report. Journal of Medical Case Reports, 2014, 8, 364.	0.4	2
54	The cost–effectiveness of strategies in coronary artery disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 805-813.	0.7	5

#	Article	IF	CITATIONS
55	Percutaneous Coronary Intervention Outcomes in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia. JAMA Internal Medicine, 2014, 174, 232.	2.6	245
56	Long-term follow-up of a randomized, controlled clinical trial of three therapeutic strategies for multivessel stable coronary artery disease in women. Interactive Cardiovascular and Thoracic Surgery, 2014, 19, 997-1001.	0.5	1
57	On-pump versus off-pump coronary artery bypass surgery in patients older than 60Âyears: five-year follow-up of MASS III trial. Journal of Cardiothoracic Surgery, 2014, 9, .	0.4	3
58	Impact of hypoglycemic agents on myocardial ischemic preconditioning. World Journal of Diabetes, 2014, 5, 258.	1.3	11
59	Balloon Aortic Valvoplasty in Patient With Severe Calcific Aortic Stenosis and Cardiogenic Shock. Journal of Medical Cases, 2014, 5, 583-586.	0.4	0
60	Association between UCP2A55V polymorphism and risk of cardiovascular events in patients with multi-vessel coronary arterial disease. BMC Medical Genetics, 2013, 14, 40.	2.1	13
61	Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial. American Heart Journal, 2013, 166, 250-257.	1.2	54
62	Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: Effect of age in the Medicine, Angioplasty, or Surgery Study II trial. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 1105-1112.	0.4	12
63	Hypotheses, rationale, design, and methods for evaluation of ischemic preconditioning assessed by sequential exercise tests in diabetic and non-diabetic patients with stable coronary artery disease – a prospective study. BMC Cardiovascular Disorders, 2013, 13, 117.	0.7	4
64	Long-term analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial. European Heart Journal, 2013, 34, 3370-3377.	1.0	16
65	Effect of Hypoglycemic Agents on Ischemic Preconditioning in Patients With Type 2 Diabetes and Symptomatic Coronary Artery Disease. Diabetes Care, 2013, 36, 1654-1659.	4.3	29
66	Cost-Effectiveness Analysis for Surgical, Angioplasty, or Medical Therapeutics for Coronary Artery Disease. Circulation, 2012, 126, S145-50.	1.6	33
67	Cancer-related deaths among different treatment options in chronic coronary artery disease. Coronary Artery Disease, 2012, 23, 79-84.	0.3	24
68	Effect of Complete Revascularization on 10-Year Survival of Patients With Stable Multivessel Coronary Artery Disease. Circulation, 2012, 126, S158-63.	1.6	56
69	Higher incidence of death in multi-vessel coronary artery disease patients associated with polymorphisms in chromosome 9p21. BMC Cardiovascular Disorders, 2012, 12, 61.	0.7	16
70	Hypotheses, rationale, design, and methods for prognostic evaluation of cardiac biomarker elevation after percutaneous and surgical revascularization in the absence of manifest myocardial infarction. A comparative analysis of biomarkers and cardiac magnetic resonance. The MASS-V Trial. BMC Cardiovascular Disorders, 2012, 12, 65.	0.7	10
71	Strategies for Multivessel Revascularization in Patients with Diabetes. New England Journal of Medicine, 2012, 367, 2375-2384.	13.9	1,573
72	The Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial: Clinical and angiographic profile at study entry. American Heart Journal, 2012, 164, 591-599.	1,2	34

#	Article	IF	CITATIONS
73	The Effect of Age on Outcomes of Coronary Artery Bypass Surgery Compared With Balloon Angioplasty or Bare-Metal Stent Implantation Among Patients With Multivessel Coronary Disease. Journal of the American College of Cardiology, 2012, 60, 2150-2157.	1.2	44
74	Coronary to bronchial artery fistula: are we treating it right?. Journal of Invasive Cardiology, 2012, 24, E303-4.	0.4	3
75	Avaliação prognóstica da doença coronária estável através de um novo escore. Arquivos Brasileiros De Cardiologia, 2011, 96, 411-419.	0.3	1
76	Genetic Variants of Diabetes Risk and Incident Cardiovascular Events in Chronic Coronary Artery Disease. PLoS ONE, 2011, 6, e16341.	1.1	7
77	The effect of internal thoracic artery grafts on long-term clinical outcomes after coronary bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 829-835.	0.4	16
78	Teratoma of the mediastinum: a case report. Journal of Medical Case Reports, 2011, 5, 193.	0.4	5
79	Effects of Optimal Medical Treatment With or Without Coronary Revascularization on Angina and Subsequent Revascularizations in Patients With Type 2 Diabetes Mellitus and Stable Ischemic Heart Disease. Circulation, 2011, 123, 1492-1500.	1.6	108
80	Preoperative B-type natriuretic peptide, and not the inflammation status, predicts an adverse outcome for patients undergoing heart surgeryâ <sup>+</sup> †. Interactive Cardiovascular and Thoracic Surgery, 2011, 12, 778-783.	0.5	12
81	Reduced expression of systemic proinflammatory and myocardial biomarkers after off-pump versus on-pump coronary artery bypass surgery: A prospective randomized study. Journal of Critical Care, 2010, 25, 305-312.	1.0	50
82	Hypotheses, rationale, design, and methods for prognostic evaluation in type 2 diabetic patients with angiographically normal coronary arteries. The MASS IV-DM Trial. BMC Cardiovascular Disorders, 2010, 10, 47.	0.7	0
83	Efficacy of aneurysmectomy in patients with severe left ventricular dysfunction: favorable short-and long-term results in ischemic cardiomyopathy. Clinics, 2010, 65, 947-952.	0.6	6
84	Five-Year Follow-Up of a Randomized Comparison Between Off-Pump and On-Pump Stable Multivessel Coronary Artery Bypass Grafting. The MASS III Trial. Circulation, 2010, 122, S48-S52.	1.6	105
85	Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery. Journal of Cardiothoracic Surgery, 2010, 5, 91.	0.4	32
86	Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease. Thrombosis Research, 2010, 125, 61-66.	0.8	28
87	Ten-Year Follow-Up Survival of the Medicine, Angioplasty, or Surgery Study (MASS II). Circulation, 2010, 122, 949-957.	1.6	284
88	Grande fÃstula bilateral da artéria coronária: a escolha do tratamento clÃnico. Arquivos Brasileiros De Cardiologia, 2009, 93, e48-9.	0.3	6
89	TCF7L2 Polymorphism rs7903146 Is Associated with Coronary Artery Disease Severity and Mortality. PLoS ONE, 2009, 4, e7697.	1.1	56
90	Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 1443-1449.	0.4	21

#	Article	IF	CITATIONS
91	In Vitro Simultaneous Transfer of Lipids to HDL in Coronary Artery Disease and in Statin Treatment. Lipids, 2009, 44, 917-24.	0.7	52
92	Factors Related to the Selection of Surgical Versus Percutaneous Revascularization in Diabetic Patients With Multivessel Coronary Artery Disease in the BARI 2D (Bypass Angioplasty) Tj ETQq0 0 0 rgBT /Overl 384-392.	ock 10 Tf	50 <i>7</i> 02 Td (R
93	Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet, The, 2009, 373, 1190-1197.	6.3	649
94	Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: a prospective randomized study. Coronary Artery Disease, 2009, 20, 100-105.	0.3	16
95	TCF7L2variant genotypes and type 2 diabetes risk in Brazil: significant association, but not a significant tool for risk stratification in the general population. BMC Medical Genetics, 2008, 9, 106.	2.1	32
96	A randomized comparative study of patients undergoing myocardial revascularization with or without cardiopulmonary bypass surgery: The MASS III Trial. Trials, 2008, 9, 52.	0.7	9
97	Long-Term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Multivessel Coronary Artery Disease. Circulation, 2008, 118, 1146-1154.	1.6	266
98	Impact of number of vessels disease on outcome of patients with stable coronary artery disease: 5-year follow-up of the Medical, Angioplasty, and bypass Surgery Study (MASS). European Journal of Cardio-thoracic Surgery, 2008, 33, 349-354.	0.6	34
99	Reply to Athappan and Subramanian. European Journal of Cardio-thoracic Surgery, 2008, 34, 703-703.	0.6	0
100	Impact of metabolic syndrome on the outcome of patients with stable coronary artery disease: 2-year follow-up of the MASS II study. Coronary Artery Disease, 2008, 19, 383-388.	0.3	12
101	Qualidade de vida após revascularização cirúrgica do miocárdio com e sem circulação extracorpórea. Arquivos Brasileiros De Cardiologia, 2008, 91, 217-22, 238-44.	0.3	18
102	Custos comparativos entre a revascularização miocárdica com e sem circulação extracorpórea. Arquivos Brasileiros De Cardiologia, 2008, 91, 369-376.	0.3	11
103	Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS II). Circulation, 2007, 115, 1082-1089.	1.6	392
104	Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris. Coronary Artery Disease, 2007, 18, 55-59.	0.3	24
105	Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization. Thrombosis Research, 2007, 121, 25-32.	0.8	20
106	Impact of Diabetes on Five-Year Outcomes of Patients With Multivessel Coronary Artery Disease. Annals of Thoracic Surgery, 2007, 83, 93-99.	0.7	39
107	Quality of life in patients with symptomatic multivessel coronary artery disease: A comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial. International Journal of Cardiology, 2007, 116, 364-370.	0.8	70
108	Efeitos do uso da adrenalina na anestesia local odontológica em portador de coronariopatia. Arquivos Brasileiros De Cardiologia, 2007, 88, 545-551.	0.3	33

#	Article	IF	Citations
109	Qualidade de vida após revascularização cirúrgica do miocárdio, angioplastia ou tratamento clÃnico. Arquivos Brasileiros De Cardiologia, 2007, 88, 537-44.	0.3	17
110	Clinical Judgment and Treatment Options in Stable Multivessel Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 48, 948-953.	1.2	35
111	Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease. Thrombosis Research, 2006, 118, 679-683.	0.8	21
112	Coronary Revascularization (Surgical or Percutaneous) Decreases Mortality After the First Year in Diabetic Subjects but not in Nondiabetic Subjects With Multivessel Disease: An Analysis From the Medicine, Angioplasty, or Surgery Study (MASS II). Circulation, 2006, 114, I-420-I-424.	1.6	43
113	Revascularização miocárdica completa, incompleta ou nenhuma. Arquivos Brasileiros De Cardiologia, 2006, 87, e144-e146.	0.3	2
114	Exercise stress testing before and after successful multivessel percutaneous transluminal coronary angioplasty. Brazilian Journal of Medical and Biological Research, 2006, 39, 475-482.	0.7	3
115	The Effects of Glibenclamide, a KATP Channel Blocker, on the Warm-Up Phenomenon. Annals of Noninvasive Electrocardiology, 2005, 10, 356-362.	0.5	18
116	One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: A meta-analysis of individual patient data from randomized clinical trials. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 512-519.	0.4	148
117	Commentary. Evidence-based Cardiovascular Medicine, 2005, 9, 54.	0.0	0
118	Effect of glycoprotein IIIa PIA2 polymorphism on outcome of patients with stable coronary artery disease and effect of smoking. American Journal of Cardiology, 2004, 93, 1469-1472.	0.7	21
119	The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease. Journal of the American College of Cardiology, 2004, 43, 1743-1751.	1.2	347
120	Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment. Journal of the American College of Cardiology, 2004, 43, 2225-2232.	1.2	30
121	Detection of retained surgical sponge by transthoracic and transesophageal echocardiography. Journal of the American Society of Echocardiography, 2003, 16, 1191-1193.	1.2	13
122	Plasma kinetics of a cholesterol-rich emulsion in subjects with or without coronary artery disease. Journal of Lipid Research, 2003, 44, 464-469.	2.0	29
123	Relative Cost Comparison of Treatments for Coronary Artery Disease: The First Year Follow-Up of MASS II Study. Circulation, 2003, 108, 21II-23.	1.6	24
124	Coronary heart disease clinical manifestation and risk factors in Japanese immigrants and their descendents in the city of São Paulo. Arquivos Brasileiros De Cardiologia, 2003, 81, 234-238.	0.3	7
125	LDL concentration is correlated with the removal from the plasma of a chylomicron-like emulsion in subjects with coronary artery disease. Atherosclerosis, 2002, 161, 447-453.	0.4	17
126	Acute pleuropulmonary complications detected by computed tomography following myocardial revascularization. Revista Do Hospital Das Clinicas, 2002, 57, 135-142.	0.5	22

#	Article	IF	CITATIONS
127	Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS): A Prospective, Randomized Trial of Medical Therapy, Balloon Angioplasty, or Bypass Surgery for Single Proximal Left Anterior Descending Coronary Artery Stenosis. Circulation, 1999, 100, II-107-II-113.	1.6	70
128	Pulmonary function after coronary artery bypass surgery. Respiratory Medicine, 1997, 91, 629-633.	1.3	64
129	VATS for complete dissection of LIMA in minimally invasive coronary artery bypass grafting. Annals of Thoracic Surgery, 1997, 63, S110-S113.	0.7	17
130	The Medicine, Angioplasty or Surgery Study (MASS): A prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. Journal of the American College of Cardiology, 1995, 26, 1600-1605.	1.2	282
131	Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet, The, 1995, 346, 1184-1189.	6.3	463
132	Relationship Between Pleural Effusion and Pericardial Involvement After Myocardial Revascularization. Chest, 1994, 105, 1748-1752.	0.4	51
133	Influence of Atelectasis on Pulmonary Function After Coronary Artery Bypass Grafting. Chest, 1993, 104, 434-437.	0.4	33
134	Ventricular Arrhythmias Induced by Programmed Ventricular Stimulation After Uncomplicated Myocardial Infarction. Angiology, 1992, 43, 578-584.	0.8	0
135	Relationship Between Pleural Changes after Myocardial Revascularization and Pulmonary Mechanics. Chest, 1992, 102, 1333-1336.	0.4	48
136	Two- to eight-year survival rates in patients who refused coronary artery bypass grafting. American Journal of Cardiology, 1989, 63, 155-159.	0.7	11
137	Coronary Bypass Surgery for Patients with Renal Transplantation. Cardiology, 1986, 73, 151-155.	0.6	4